$0.84 -0.04 (-4.22%) Sunesis Pharmaceuticals Inc - NASDAQ

Aug. 30, 2016 | 02:57 PM
Last Trade: 0.84
Trade Time: Aug 30 02:57 PM Eastern Daylight Time
Change: -0.04 (-4.22%)
Prev Close: 0.88
Open: 0.86
Bid: 0.84
Ask: 0.84
  1. No results found.
  1. Roundys Among Largest Insiders' Buys of the Week

    GuruFocus | Dec. 31, 2015 | 12:35PM EST
  2. Sunesis Pharmaceuticals Announces Submission of a Marketing Authorization Application for Vosaroxin for the Treatment of Acute Myeloid Leukemia in Europe

    Benzinga | Dec. 8, 2015 | 07:02AM EST
  3. Sunesis Pharmaceuticals Announces Presentation of Results Phase 1 Trial of Vosaroxin + Azacitidine at #ASH2015

    Benzinga | Dec. 6, 2015 | 08:41AM EST
  4. Sunesis Pharma Reports Presentation of Responder Survival Analysis from Phase 3 VALOR Trial at CFS

    Benzinga | Nov. 4, 2015 | 18:02PM EST
  5. Sunesis Announces Anticipated Submission of European Marketing Authorization Application for Vosaroxin in AML Before Year End

    Benzinga | Oct. 7, 2015 | 16:05PM EST
  6. Biotech Stocks Falling Broadly, Here's Why And How Much

    Benzinga | Jul. 26, 2015 | 21:57PM EST
  7. Worst Performing Industries For July 24, 2015

    Benzinga | Jul. 24, 2015 | 11:30AM EST
  8. Sunesis Pharma Offers New Data from VALOR Trial for Vosaroxin in Oilder Patients with Acute Myeloid Leukemia

    Benzinga | Jun. 12, 2015 | 07:01AM EST
  9. Sunesis Pharmaceuticals Announces Presentations of VALOR Data at the 20th Congress of the European Hematology Association

    Benzinga | May. 21, 2015 | 08:13AM EST
  10. BTIG Initiates Coverage On Sunesis Pharmaceuticals, Believes Company 'Will Be Breakeven By 2017'

    Benzinga | Jan. 5, 2015 | 19:19PM EST
  11. Sunesis Announces Presentation Of Positive Updated Results From Ongoing MD Anderson-Sponsored Trial Of Vosaroxin In AML And High-Risk MDS at ASH Annual Meeting

    Benzinga | Dec. 8, 2014 | 13:32PM EST
  12. Morning Market Losers

    Benzinga | Dec. 8, 2014 | 09:53AM EST
  13. UPDATE: Sunesis Reports Schedule C Had Most Favorably Safety/Efficacy Balance

    Benzinga | Nov. 24, 2014 | 07:24AM EST
  14. Sunesis Announces Publication Of Vosaroxin Phase 1b/2 AML Trial Results In Haematologica

    Benzinga | Nov. 19, 2014 | 07:01AM EST
  15. Sunesis Pharmaceuticals Announces Late-Breaking Presentation Of Phase 3 VALOR Trial At ASH Annual Meeting

    Benzinga | Nov. 17, 2014 | 09:06AM EST
Trading Center